Open AccessEndoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects
Author(s) -
Shenxia Xie,
Xiaoqiong Hou,
Wei Yang,
Wei Shi,
Xiaomei Yang,
Siliang Duan,
Fengzhen Mo,
Ai Qun Liu,
Wei Wu,
Xiaoling Lü
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s317220
Subject(s) - cancer research , tumor microenvironment , cytotoxic t cell , immunotherapy , cd8 , t cell , angiogenesis , immune system , chemistry , immunology , medicine , in vitro , biochemistry
The broader application of adoptive cell therapy (ACT) in cancer immunotherapies (particularly for solid tumors) has always been limited by the immunosuppressive tumor microenvironment (TME) and the insufficient targetability of effector T cells, resulting in unsatisfied therapeutic outcome. Here, we designed a new strategy by using aptamer-based immunoliposomes to modify PD-1-silencing T cells, which were activated by dendritic cell (DC)/tumor fusion cells (FCs) to improve the antitumor potency of cytotoxic T lymphocytes (CTLs/CD8 + T cells).